Impact of biological and non-biological treatment on hematological indices in patients with ankylosing spondylitis and psoriatic arthritis

Egyptian Rheumatology and Rehabilitation

Table 4 Comparison between AS patients with and without biologic therapy as regards WBCs, RBCs, and platelets indices

AS	Biologics						t test
	Non-biologics			Biologics			t test
	Mean	±	SD	Mean	±	SD	t	P value
WBCS	7.150	±	1.375	6.514	±	2.049	1.43	0.159
Neutrophils	4.116	±	0.997	3.843	±	1.605	0.80	0.426
Lymphocytes	2.616	±	0.809	2.246	±	0.737	1.84	0.071
HCT	37.713	±	3.451	38.63	±	2.903	− 1.104	0.274
RBCs	4.832	±	0.617	5.011	±	0.672	− 1.074	0.287
Hb	12.750	±	1.527	13.24	±	1.749	− 1.157	0.252
MCV	78.072	±	6.004	78.49	±	8.498	− 0.224	0.824
MCH	25.509	±	3.880	25.27	±	4.020	0.237	0.814
RDW%	13.984	±	1.538	12.37	±	1.201	4.480	< 0.001
PLT	301.7	±	84.9	318.71	±	153.9	− 0.538	0.592
MPV/fl	9.491	±	1.31	9.929	±	3.12	− 0.726	0.471
PDW	11.409	±	2.693	11.511	±	2.84	− 0.142	0.888
Hb/PLT ratio	0.047	±	0.017	0.050	±	0.019	− 0.739	0.463
RDW%/PLT ratio	0.049	±	0.014	0.046	±	0.018	0.80	0.428
RBCs/PLT ratio	0.018	±	0.007	0.019	±	0.007	− 1.034	0.306
Hb/RDW% ratio	0.923	±	0.146	1.081	±	0.179	− 3.78	< 0.001
Neutrophil/lymphocyte ratio	1.733	±	0.749	1.847	±	1.065	− 0.48	0.630
PLT/lymphocyte ratio	129.91	±	57.23	151.26	±	66.09	− 1.34	0.185

AS ankylosing spondylitis, DD disease duration, WBCs white blood cells, HCT hematocrit, RBCs red blood cells, HB hemoglobin, MCV mean corpuscular volume, MCH mean corpuscular hemoglobin, RDW red cell distribution width, PLT platelet, MPV mean platelet volume, PDW platelet distribution width, SD standard deviation. Level of significance: P ≤ 0.05: significant, P < 0.005: highly significant